The estimated Net Worth of Badrul A. Chowdhury is at least $1.57 Million dollars as of 9 December 2021. Dr Chowdhury owns over 25,000 units of Savara Inc stock worth over $756,000 and over the last 6 years he sold SVRA stock worth over $0. In addition, he makes $816,959 as Chief Medical Officer at Savara Inc.
Dr has made over 2 trades of the Savara Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of SVRA stock worth $26,250 on 9 December 2021.
The largest trade he's ever made was exercising 200,000 units of Savara Inc stock on 15 May 2021 worth over $864,000. On average, Dr trades about 32,143 units every 30 days since 2019. As of 9 December 2021 he still owns at least 175,000 units of Savara Inc stock.
You can see the complete history of Dr Chowdhury stock trades at the bottom of the page.
Dr. Badrul A. Chowdhury M.D., Ph.D. is the Chief Medical Officer at Savara Inc.
As the Chief Medical Officer of Savara Inc, the total compensation of Dr D at Savara Inc is $816,959. There are no executives at Savara Inc getting paid more.
Dr D is 63, he's been the Chief Medical Officer of Savara Inc since . There are 2 older and 9 younger executives at Savara Inc. The oldest executive at Savara Inc is Richard Hawkins, 71, who is the Independent Director.
Badrul's mailing address filed with the SEC is 6836 BEE CAVE ROAD, BUILDING III, SUITE 201, AUSTIN, TX, 78746.
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Savara Inc executives and other stock owners filed with the SEC include: